Inomax 800 ppm mol/mol, medicinal compressed gas
SpainTable of Contents
Package leaflet: Information for the user
Introduction
PACKAGE LEAFLET: INFORMATION FOR THE USER
INOmax 800 ppm mol/mol, medicinal compressed gas
nitric oxide
Read the entire leaflet carefully before you start using this medicine, because it contains important information for you.
- Keep this leaflet, as you may need to read it again. If you have any questions, consult your doctor.
- If you experience any adverse reactions, consult your doctor, even if they are adverse reactions not listed in this leaflet. See section 4.
Leaflet contents:
- What INOmax is and what it is used for
- What you need to know before using INOmax
- How to use INOmax
- Possible adverse effects
- Storage of INOmax
- Contents of the pack and other information
1. What INOmax is and what it is used for
INOmax contains nitric oxide, a gas used for the treatment of:
newborns with respiratory failure associated with high blood pressure in the lungs,
a condition known as hypoxic respiratory failure. When inhaled, this gas mixture can improve blood flow through the lungs, which may help increase the amount of oxygen reaching the infant's blood.
newborns, infants, children and young patients aged 0–17 years, and adults with pulmonary hypertension related to cardiac surgery. This gas mixture may improve cardiac function and increase blood flow in the lungs, which may help increase the amount of oxygen reaching the blood.
2. What you need to know before using INOmax
Do not use INOmax:
-
If you (as a patient) or your child (as a patient) are allergic (hypersensitive) to nitric oxide or to any of the components of INOmax (see section 6 “Additional information” for the complete list of ingredients).
-
If you have been informed that you (as a patient) or your child (as a patient) have an abnormal blood circulation in the heart.
Take special care with INOmax
Inhaled nitric oxide is not always effective, so other treatments may sometimes need to be considered for you or your child.
Inhaled nitric oxide may affect the blood's ability to carry oxygen. This will be monitored through blood tests and, if necessary, by reducing the dose of inhaled nitric oxide.
Nitric oxide may react with oxygen and form nitrogen dioxide, which can cause irritation of the airways. Your doctor or your child’s doctor will monitor nitrogen dioxide levels and, if elevated levels are detected, will appropriately reduce the INOmax treatment.
Inhaled nitric oxide may have a slight effect on your platelets (components that help blood to clot) or on those of your child, so any signs of bleeding or bruising should be monitored. If you notice any signs or symptoms that could be associated with bleeding, inform your doctor immediately.
There is no documented effect of inhaled nitric oxide in newborns with a malformation in which the diaphragm is incomplete, known as congenital diaphragmatic hernia.
In newborns with specific heart malformations, what doctors call congenital heart disease, inhaled nitric oxide may worsen circulation.
Cases of fluid retention in the lungs have been reported with nitric oxide in patients suffering from a condition caused by a blocked or narrowed vein in the lungs. If you (as a patient) or your child (as a patient) experience shortness of breath or difficulty breathing, contact your doctor immediately.
Children
INOmax should not be administered to premature infants with < 34 weeks of gestation.
Use of INOmax with other medicines:
Your doctor will decide when to treat you or your child with INOmax and other drugs, and will carefully monitor the treatment.
Inform your doctor if you (as a patient) or your child (as a patient) are taking or have recently taken or used any other medications, including medicines obtained without a prescription.
Some medicines may affect the blood's ability to carry oxygen, such as prilocaine (a local anesthetic used to relieve pain during minor painful procedures, such as suturing or minor surgical or diagnostic procedures) or glyceryl trinitrate (used to treat angina). Your doctor will check that the blood contains sufficient oxygen when these medicines are being used.
Pregnancy and breastfeeding
INOmax is not recommended during pregnancy and breastfeeding. Before starting treatment with INOmax, inform your doctor if you are pregnant, think you may be pregnant, or are breastfeeding.
Consult your doctor or pharmacist before taking any medicine.
Driving and using machines
Not applicable
INOmax contains nitrogen
3. How to use INOmax
Your doctor will determine the correct dose of INOmax and will administer INOmax to your lungs or to those of your child using a system designed for the delivery of this gas. This delivery system will ensure that the correct amount of nitric oxide is administered by diluting INOmax with a mixture of oxygen and air immediately before administration.
For your safety or that of your child, systems intended for the administration of INOmax are equipped with continuous monitoring devices that measure the amounts of nitric oxide, oxygen, and nitrogen dioxide (a chemical formed when nitric oxide is mixed with oxygen) being delivered to the lungs.
Your doctor will determine how long the treatment with INOmax should last.
INOmax is administered at doses of 10–20 ppm (parts per million) (maximum dose: 20 ppm in children and 40 ppm in adults) in the gas inhaled by you or your child. The lowest effective dose will be sought.
Treatment typically lasts about 4 days in newborns with lung failure associated with pulmonary hypertension. In children and adults with pulmonary hypertension related to heart surgery, INOmax is usually administered for 24–48 hours. However, treatment with INOmax may be extended.
If you or your child receive more INOmax than you should
An excessive amount of inhaled nitric oxide may affect the blood's ability to carry oxygen. This will be assessed through blood tests, and if necessary, the dose of INOmax will be reduced and medications such as vitamin C or methylene blue may be administered. In some cases, a blood transfusion may be considered to improve oxygen-carrying capacity.
If treatment with INOmax is interrupted
Treatment with INOmax must not be stopped suddenly. Sudden interruption of INOmax treatment without prior dose reduction has been associated with hypotension or rebound increase in pulmonary pressure.
At the end of treatment, your doctor will gradually reduce the amount of INOmax administered to you or your child, allowing the pulmonary circulation to adjust to oxygen/air without the need for INOmax. This process may take one or two days before administration of INOmax is completely discontinued.
If you have any further questions about the use of this medicine, ask your doctor.
4. Possible adverse effects
Like all medicines, this medicine may cause adverse effects, although not everyone experiences them. Your doctor will carefully examine you or your child to identify any adverse effects.
Very common adverse effects (affecting more than 1 in 10 patients) associated with INOmax treatment include:
- Low platelet count.
Common adverse effects (affecting more than 1 in 100 patients) associated with INOmax treatment include:
- Hypotension, pulmonary collapse, or lack of oxygen in the lungs.
Adverse effects that may occur and are uncommon (affecting between 1 in 100 and 1 in 1,000 patients) include:
- Increased methemoglobin, leading to reduced oxygen-carrying capacity.
Adverse effects observed but with unknown frequency (cannot be estimated from available data) include:
-
Bradycardia (low heart rate) or excessively low blood oxygen levels (oxygen desaturation/hypoxemia) due to sudden interruption of treatment.
-
Headache, dizziness, dry throat, or breathing difficulties following accidental exposure to nitric oxide in the environment (e.g., equipment leaks or gas cylinder leaks).
You should inform the medical staff immediately if you experience headache while being near your child receiving INOmax.
If you consider any of the adverse effects you experience to be severe, or if you notice any adverse effects not listed in this leaflet—even after you or your child have left the hospital—inform your doctor.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if these are possible adverse effects not listed in this leaflet. You may also report them directly through the national reporting system listed in Annex V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of INOmax
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the label following CAD. The expiry date refers to the last day of that month.
Treatment with INOmax must only be administered and handled by hospital personnel.
- INOmax cylinders must be securely stored to prevent falling and, consequently, potential damage.
- INOmax must be handled and administered only by personnel specifically trained in the use and handling of INOmax.
Regulations regarding the handling of pressurized gas cylinders must be observed.
Storage is supervised by hospital specialists. Store gas cylinders in well-ventilated rooms or ventilated sheds, protected from rain and direct sunlight.
Protect gas cylinders from impact, falls, oxidation, flammable materials, moisture, and sources of heat or ignition.
Storage in the pharmacy department
Gas cylinders must be stored in a well-ventilated, clean, and locked area, designated exclusively for the storage of medicinal gases. Within this area, there must be a separate, dedicated installation for the storage of nitric oxide gas cylinders.
Storage in the medical department
The gas cylinder must be placed in an area equipped with appropriate equipment to ensure it remains in an upright position.
Do not discard the gas cylinder when empty. Empty gas cylinders will be collected by the supplier.
6. Contents of the pack and other information
Composition of INOmax
The active substance in INOmax is nitric oxide 800 ppm mol/mol. A 2-litre gas cylinder filled to 155 bar absolute contains 307 litres of gas at a pressure of 1 bar at 15 °C.
A 10-litre gas cylinder filled to 155 bar absolute contains 1.535 litres of gas at a pressure of 1 bar at 15 °C.
The other ingredient is nitrogen.
Presentation and contents of the INOmax pack
Medicinal compressed gas
Aluminium 2-litre gas cylinder (identified with an aquamarine shoulder and white body),
filled to a pressure of 155 bar, with a stainless steel positive pressure (residual) valve with a specific outlet connection and a standard valve handwheel.
Aluminium 2-litre gas cylinder (identified with an aquamarine shoulder and white body),
filled to a pressure of 155 bar, with a stainless steel positive pressure (residual) valve with a specific outlet connection and a valve handwheel equipped with an INOmeter device.
Aluminium 10-litre gas cylinder (identified with an aquamarine shoulder and white body),
filled to a pressure of 155 bar, with a stainless steel positive pressure (residual) valve with a specific outlet connection and a standard valve handwheel.
Aluminium 10-litre gas cylinder (identified with an aquamarine shoulder and white body),
filled to a pressure of 155 bar, with a stainless steel positive pressure (residual) valve with a specific outlet connection and a valve handwheel equipped with an INOmeter device.
INOmax is available in 2-litre and 10-litre aluminium gas cylinders.
Marketing Authorisation Holder
Linde Healthcare AB
Rättarvägen 3
169 68 Solna
Sweden
Manufacturer
Linde France
Z.I. Limay-Porcheville
3 avenue Ozanne
78440 Porcheville
France
For further information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Belgium/Belgium/Belgium Linde Gas Belgium N.V. Westvaartdijk 85 1850 Grimbergen Tel/Tel.: +32 70 233 826 | Lithuania Linde Gas UAB Didlaukio g. 69 08300, Vilnius Tel.: +370 2787787 |
| Luxembourg/Luxembourg Linde Gas Belgium N.V. Westvaartdijk 85 1850 Grimbergen Tel.: +32 70 233 826 |
Czech Republic Linde Gas a.s. U Technoplynu 1324 198 00 Praha 9 Tel: +420 800 121 121 | Hungary Linde Gáz Magyarország Zrt. Illatos út 11/A. 1097 Budapest Tel.: +36 30 349 2237 |
Denmark Linde Gas A/S Lautruphøj 2-6 2730 Ballerup Tlf: +45 70 104 103 | Malta Linde Medicale S.r.L Via Guido Rossa 3 I - 20004 Arluno (MI) Tel: +39 02 903731 / 800 600 633 |
Germany Linde GmbH 82049 Pullach Tel: +49 89 7446 0 | Netherlands Linde Gas Therapeutics Benelux B.V. De Keten 7 5651 GJ Eindhoven Tel: +31 40 282 58 25 |
Estonia AS Linde Gas Valukoja 8 11415 Tallinn Tel: +372 650 4500 | Norway Linde Gas AS Postboks 13 Nydalen 0409 Oslo Tlf. +47 81559095 |
Greece LINDE ELLAS MON EPE Thesi Tripiou Lithri 19600 Mandra Attikis Tel: +30 211-1045500-510 | Austria Linde Healthcare Linde Gas GmbH Modecenterstr.17/ Objekt 1/3.OG 1110 Wien Tel: +43(0)50.4273-2200 |
Spain Linde Gas España, S.A.U. Camino de Liria, s/n 46530 Puzol (Valencia) Tel: +34 900 941 857 / +34 902 426 462 | Poland Linde Gaz Polska Sp. z o.o. ul. prof Michala Zyczkowskiego 17 31-864 Krakow Tel.: 0 801 142 748 / +48 (12) 643 92 00 |
France Linde France - Medical Activity - Linde Healthcare 3 avenue Ozanne Z.I. Limay-Porcheville 78440 Porcheville Tel: +33 810 421 000 | Portugal Linde Portugal, Lda. Av. Infante D. Henrique Lotes 21-24 1800-217 Lisboa Tel: +351 218 310 420 |
Croatia Linde Healthcare AB Rättarvägen 3 S - 169 68 Solna Tel: +46 8 7311000 | Romania Linde Gaz România SRL str. Avram Imbroane nr. 9 Timisoara 300136 - RO Tel: +40 256 300 700 |
Ireland INO Therapeutics UK 185 Carver Drive Kent Science Park Sittingbourne Kent ME9 8NP Tel: +44 1795 411552 | Slovenia Linde Healthcare AB Rättarvägen 3 S - 169 68 Solna Tel: +46 8 7311000 |
Iceland Linde Gas ehf Breiðhöfða 11 110 Reykjavik Sími: +354 577 3030 | Slovakia Linde Gas s.r.o. Tuhovská 3 SK - 831 06 Bratislava Tel: +421 800 154 633 |
Italy Linde Medicale S.r.L Via Guido Rossa 3 20010 Arluno (MI) Tel: +39 02 903731 / 800 600 633 | Finland Oy Linde Gas Ab Itsehallintokuja 6 02600 Espoo Puh/Tel: +358 10 2421 |
Cyprus Linde Hadjikyriakos Gas Ltd Leoforos Lemesou 260, 2029 Strouvolos Nicosia, Cyprus. Tel. +357-22482330 | Sweden Linde Gas AB Rättarvägen 3 169 68 Solna Tel: +46 8 7311800 |
Latvia Linde Gas SIA, Katrinas iela 5 Riga, 1045 Tel: +371 80005005 |
Date of the most recent review of this leaflet: MM/YYYY
Other sources of information
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu
